Royalty Report: Medical, Device, Respiratory – Collection: 26420


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Medical
  • Device
  • Respiratory
  • Diagnostic
  • Mobile
  • Scientific & Technical Instruments
  • Therapeutic
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26420

License Grant
UNIVERSITY hereby grants to LICENSEE, and LICENSEE hereby accepts, an exclusive option and license under Patent Rights to make and have made, to use and have used, to sell and have sold, to offer for sale, and to import and have imported Licensed Products and to practice Licensed Methods, in the Field within the Territory and during the Term.

The license granted includes the right of LICENSEE to grant Sublicense to third parties during the Term.

License Property
The invention disclosed in UCSD Disclosure Docket No. SD2010-344 and titled 'A New Supplemental Oxygen Delivery System with Automated Adaptive Control'.

The License technology relates to oxygen delivery devices that incorporate a computer controlled, patient-adaptive dosing system, for people who use supplemental oxygen therapy.

SOS’s Intended Products
The full function products that SOS plans to develop include stationary and mobile versions of a supplemental oxygen delivery control device that uses, for each breath, blood oxygen readings and inhaled breath depth measurements to deliver an appropriate oxygen flow to satisfy the user’s need. As a user requires a greater volume of oxygen, the SOS device would be designed to automatically respond, breath by breath, to deliver the appropriate oxygen dose. Blood oxygen readings would be taken by an integrated pulse oximeter (a non-invasive monitoring device) attached to the user’s finger or ear. Inhaled breath depth measurements would be taken from the air hose that delivers the oxygen to the user. Unlike continuous-flow supplemental oxygen delivery devices, the planned SOS device would not deliver oxygen flow while the user is exhaling, and thus may serve an oxygen conserving function as well.

'Patent Rights' means UNIVERSITY's rights in any of the following: the US patent application (serial number 13/814,934 titled 'Automated Fluid Delivery System and Method').

Field of Use
'Field' means Oxygen therapy devices and methods with and without Pulse Oximetry Feedback.

The Licensee will try to develop a supplemental oxygen delivery device that would incorporate a computer controlled, patient-adaptive dosing system for use by people who require supplemental oxygen therapy.  The device is may be used by people who have been prescribed supplemental oxygen by their doctor. It is being developed to deliver the benefit of an oxygen conserving device and the benefit of delivering a dose of oxygen commensurate with demand.

IPSCIO Record ID: 1153

License Grant
The Licensee has entered into an exclusive license agreement, with the right to sublicense, with the Licensors, the individuals, for the Oxymixer device, with respect to that device and each of the additional oxygen conserving devices developed by them. At the present time, the Licensee has licensed the Oxymizer device, the Oxymizer Pendant device and the Oxymatic Conserver, thereby acquiring exclusive rights to manufacture and market such products.
License Property
The Oxymizer is a disposable oxygen-conserving device, a unique, patented device developed to provide up to 4 to1 savings of oxygen when used with any oxygen supply source.
Field of Use
The field of use relates to respiratory care devices designed to improve the efficiency of oxygen delivery systems for both home and hospital treatment of patients who require supplemental oxygen.

IPSCIO Record ID: 27802

License Grant
Assignor does hereby sell, assign, transfer and convey unto the Assignee the entire right, title and interest (a) in and to the Patents; (b) in and to all rights to apply for foreign patents on the Patents pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on the Patents in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.
License Property
The agreement covers patents and applications for Metabolic Gas Exchange and Non-invasive Cardiac Output Monitor, Respiratory Calorimeter, Metabolic Calorimeter Employing Respiratory Gas Analysis, Oxygen Consumption Meter, Respiratory Calorimeter with Bidirectional Flow Monitors for Calculating of Oxygen Consumption and Carbon Dioxide Production, Respiratory Calorimeter with Bidirectional Flow Monitors, Method and Apparatus for Respiratory Gas Analysis Employing Measurement of Expired Gas Mass, Method and Apparatus for the Non-invasive Determination of Cardiac Output, Airway-based Cardiac Output Monitor and Methods for using same, O2 Consumpt. Meter, A System and Method of Metabolic Rate Measurement, Health Improvement System and Method, Improved Systems and Methods for Drug Administration.

IPSCIO Record ID: 6696

License Grant
This License Agreement is established between the Licensee, of the Republic of South Africa, and the Licensor. Both Parties are in the business of the manufacture and distribution of certain oxygen medical devices and health care products.  The Licensor grants the Licensee the non-exclusive right to use, distribute, market, sell or subLicense, in the SADC countries, the Licensor IP, which are embedded in the Derivative Licensee products. This License includes a non-exclusive right to grant to others the perpetual, non-exclusive subLicenses use as long as the Licensor agrees in writing.
License Property
Patents include, but are not limited to:
US Patent# 7,407,632 entitled Apparatus and delivery of medically pure oxygen;
US Patent# 7,381,377 entitled Method for controlled production of a gas;
US Patent# 7,465,428 entitled Method and apparatus for controlled production of a gas;
US Patent# D549,341 entitled Breathing device utilizing a catalytic oxygen generation method;
US Patent# D549,342 entitled Breathing device utilizing a catalytic oxygen generation method;
US Patent# D/320,358 entitled Chemical reaction activation plunger;
South African Patent # 2006/5051 entitled Method and apparatus for generating oxygen.
Field of Use
Licensee is in the business of manufacturing and distribution of medical devices and health care products.

IPSCIO Record ID: 28235

License Grant
The Amendment expands the scope of the Licensee's license from the Licensor. Under the Cross-License Amendment, the Licensee will continue to develop the pulse program in the field of cardiopulmonary disease.
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices.

INOpulse is based on the Company’s proprietary pulsatile nitric oxide delivery device. The Company is currently developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension, or PAH, for which the Company intends to commence Phase 3 clinical trials in the second half of 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH COPD, which is in Phase 2 development.

The INOpulse device is designed to be portable for use by ambulatory patients on a daily basis inside or outside their homes. The device is programmed to automatically adjust based on a patient’s breathing pattern to deliver a constant and appropriate dose of the inhaled nitric oxide over time, independent of the patient’s activity level, thus ensuring more consistent dosing in the alveoli of the lungs. In addition, we have developed a proprietary triple-lumen nasal cannula which enables more accurate delivery of the dose to the patient. The INOpulse device is also compatible with many long-term oxygen therapy systems that operate via a nasal cannula.

Field of Use
The Licensee will develop its Licensor pulse program for the treatment of three additional cardiopulmonary diseases: chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness.

IPSCIO Record ID: 3240

License Grant
The cross-licensing agreement with the Licensee, who is Licensor's development partner, is granting an exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® owned by the Licensor for the monitoring of non-vital signs measurements and to develop and sell devices incorporating Masimo SET® for monitoring non-vital signs measurements in the Licensee Market.

The Licensor also granted the Licensee a non-exclusive, perpetual and worldwide license, with sublicense rights, to use Masimo SET® for the measurement of vital signs in the Licensee  Market.

Pursuant to the Cross-Licensing Agreement, the Licensor has licensed from the Licensee the right to make and distribute products in the Licensor Market that utilize rainbow® technology for the measurement of only carbon monoxide, methemoglobin, fractional arterial oxygen saturation and hemoglobin, which includes hematocrit

License Property
The Licensor invented Masimo Signal Extraction Technology®, or Masimo SET®, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. Pulse oximetry is the noninvasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body's tissues, and pulse rate.

Rainbow® SET platform utilizing both Masimo SET® and licensed rainbow® technology, includes devices cleared by the U.S. Food and Drug Administration, to noninvasively and continuously monitor multiple measurements that previously required invasive or complicated procedures.

Field of Use
The Licensee Market is defined as any product market in which a product is intended to be used by a patient or pharmacist rather than a professional medical caregiver regardless of the particular location of the sale, including sales to doctors, hospitals, alternate care market professionals or otherwise, provided the product is intended to be recommended, or resold, for use by the patient or pharmacist.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.